{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:39:15Z","timestamp":1783021155278,"version":"3.54.6"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["40007527"],"award-info":[{"award-number":["40007527"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VirEOS2"],"award-info":[{"award-number":["VirEOS2"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108242","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:41:29Z","timestamp":1763772089000},"page":"108242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Rationalizing and mitigating the risk of live-attenuated dengue vaccines"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-9166","authenticated-orcid":false,"given":"Kai","family":"Dallmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeranddy A.","family":"Alpizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108242_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.108062","article-title":"Severe dengue hemorrhagic fever after TAK-003 dengue vaccination: a case report of a potential vaccine-associated adverse reaction","volume":"160","author":"Rattanaumpawan","year":"2025","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108242_bib0002","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","article-title":"Yellow fever vaccine-associated viscerotropic disease and death in Spain","volume":"36","author":"Doblas","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ijid.2025.108242_bib0003","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2006.01.009","article-title":"Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil","volume":"24","author":"Engel","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2025.108242_bib0004","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2013.09.030","article-title":"Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review","volume":"31","author":"Rafferty","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2025.108242_bib0005","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2025.108242_bib0006","doi-asserted-by":"crossref","first-page":"taad160","DOI":"10.1093\/jtm\/taad160","article-title":"Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights","volume":"31","author":"Le Hir","year":"2024","journal-title":"J Travel Med"},{"key":"10.1016\/j.ijid.2025.108242_bib0007","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijid.2025.108242_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250164","article-title":"Autoantibodies targeting type I interferons: prevalence, mechanisms of induction, and association with viral disease susceptibility","volume":"53","author":"Hale","year":"2023","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2025.108242_bib0009","article-title":"Recommendations for dengue vaccine implementation in the elderly population","volume":"13","author":"Giang","year":"2025","journal-title":"Ther Adv Vaccin Immunother"},{"key":"10.1016\/j.ijid.2025.108242_bib0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jac\/dkae484","article-title":"Sofosbuvir as post-exposure prophylaxis for yellow fever-associated viscerotropic disease (YEL-AVD)","volume":"80","author":"Barrett","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"21","key":"10.1016\/j.ijid.2025.108242_bib11","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2500179","article-title":"Daily mosnodenvir as dengue prophylaxis in a controlled human infection model","volume":"393","author":"Durbin","year":"2025","journal-title":"N Engl J Med"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:50:14Z","timestamp":1783018214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225004643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":11,"alternative-id":["S1201971225004643"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108242","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationalizing and mitigating the risk of live-attenuated dengue vaccines","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108243","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108062","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108242"}}